Cresemba Capsule
NDC Package 0469-2860-35
Package Information
Cresemba (isavuconazonium sulfate) capsules is a medication used to treat certain serious fungal infections. This formulation utilizes a capsule delivery system. Marketed by Astellas Pharma Us, Inc., this product is identified by NDC 0469-2860 and is authorized under FDA application NDA207500.
Identification & Billing
- RxCUI: 1608327 - isavuconazonium sulfate 186 MG Oral Capsule
- RxCUI: 1608327 - isavuconazonium sulfate 186 MG (isavuconazole 100 MG) Oral Capsule
- RxCUI: 1608333 - Cresemba 186 MG Oral Capsule
- RxCUI: 1608333 - isavuconazonium sulfate 186 MG Oral Capsule [Cresemba]
- RxCUI: 1608333 - Cresemba 186 MG (isavuconazole 100 MG) Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0469 - Astellas Pharma Us, Inc.
- 0469-2860 - Cresemba
- 0469-2860-35 - 7 BLISTER PACK in 1 CARTON / 5 CAPSULE in 1 BLISTER PACK
- 0469-2860 - Cresemba
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0469-2860-35 identifies a specific commercial package of 7 blister pack in 1 carton / 5 capsule in 1 blister pack of Cresemba, a human prescription drug labeled by Astellas Pharma Us, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 7 billable units per package. This capsule is formulated for oral use and contains isavuconazonium sulfate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Astellas Pharma Us, Inc. on November 22, 2022. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat certain serious fungal infections. This medication is known as an azole antifungal. It works by stopping the growth of fungi.
How is this Astellas Pharma Us, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00469286035. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 7 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.